238 related articles for article (PubMed ID: 27336356)
1. Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome.
Gourgari E; Lodish M; Keil M; Sinaii N; Turkbey E; Lyssikatos C; Nesterova M; de la Luz Sierra M; Xekouki P; Khurana D; Ten S; Dobs A; Stratakis CA
J Clin Endocrinol Metab; 2016 Sep; 101(9):3353-60. PubMed ID: 27336356
[TBL] [Abstract][Full Text] [Related]
2. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
3. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
Zhou R; Bird IM; Dumesic DA; Abbott DH
J Clin Endocrinol Metab; 2005 Dec; 90(12):6630-7. PubMed ID: 16174719
[TBL] [Abstract][Full Text] [Related]
4. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
5. Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome.
Putignano P; Bertolini M; Losa M; Cavagnini F
J Endocrinol Invest; 2003 Jun; 26(6):539-44. PubMed ID: 12952368
[TBL] [Abstract][Full Text] [Related]
6. Ovarian influence on adrenal androgen secretion in polycystic ovary syndrome.
Fruzzetti F; De Lorenzo D; Ricci C; Teti G
Fertil Steril; 1995 Apr; 63(4):734-41. PubMed ID: 7890056
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
8. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
9. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
10. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS
J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
[TBL] [Abstract][Full Text] [Related]
11. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.
Rosenfield RL; Mortensen M; Wroblewski K; Littlejohn E; Ehrmann DA
Hum Reprod; 2011 Nov; 26(11):3138-46. PubMed ID: 21908468
[TBL] [Abstract][Full Text] [Related]
12. The adrenal and polycystic ovary syndrome.
Yildiz BO; Azziz R
Rev Endocr Metab Disord; 2007 Dec; 8(4):331-42. PubMed ID: 17932770
[TBL] [Abstract][Full Text] [Related]
13. Steroid hormone analysis of adolescents and young women with polycystic ovarian syndrome and adrenocortical dysfunction using UPC
Swart AC; du Toit T; Gourgari E; Kidd M; Keil M; Faucz FR; Stratakis CA
Pediatr Res; 2021 Jan; 89(1):118-126. PubMed ID: 32247282
[TBL] [Abstract][Full Text] [Related]
14. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
15. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
[TBL] [Abstract][Full Text] [Related]
16. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
Gambineri A; Forlani G; Munarini A; Tomassoni F; Cognigni GE; Ciampaglia W; Pagotto U; Walker BR; Pasquali R
J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
[TBL] [Abstract][Full Text] [Related]
17. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
18. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome.
Gonzalez F; Chang L; Horab T; Lobo RA
Fertil Steril; 1996 Sep; 66(3):354-61. PubMed ID: 8751729
[TBL] [Abstract][Full Text] [Related]
19. Androgens in Menopausal Women: Not Only Polycystic Ovary Syndrome.
Kostakis EK; Gkioni LN; Macut D; Mastorakos G
Front Horm Res; 2019; 53():135-161. PubMed ID: 31499509
[TBL] [Abstract][Full Text] [Related]
20. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
